前列腺癌的Gleason评分及PSA、PAP、P504S免疫表达分析  

Gleason scores for prostate cancer and immunoexpressions of PSA, PAP, and P504S

作　　者：孙红玲[1] 纪卫东[1] 陈美珠[1] 

机构地区：[1]广州医学院第一附属医院,广州510120

出　　处：《国际医药卫生导报》2013年第15期2260-2262,共3页International Medicine and Health Guidance News

基　　金：国家自然基金项目（81271350）

摘　　要：目的分析转移性与非转移性前列腺癌的Gleason评分及免疫表达的差异，为临床护理提供依据。方法选取我院泌尿外科收治的经病理组织形态学确诊的无转移性前列腺癌患者45例和转移性前列腺癌患者36例，对其前列腺组织标本的Gleason评分及相关标记物PSA、PAP、P504S的免疫表达进行分析。结果转移性前列腺癌患者的Gleason评分[（7．36±1．22分]高于无转移性患者的评分[（6．55±1．12）分]，经秩和检验，差异有统计学意义（P〈0．05）。≥71岁患者的免疫组化PSA、PAP含量≥（＋＋）的阳性患者多于≤70岁的患者，差异有统计学意义（P〈0．05）。81例前列腺癌中，71例P504S呈阳性表达，占87．7％。结论Gleason评分及PSA、PAP、P504S的免疫表达，能较准确地评估病情，促进护理随访和咨询质量。Objective To provide support for clinical nursing by analyzing the Gleason scores and immunoexpressions in metastatic and non-metastatic prostate cancer. Methods 45 patients wih non-metastatic prostate cancer and 36 with metastatic prostate carcinoma diagnosed by pathological histology were chosen from the First Affiliated Hospital of Guangzhou Medical University. The Gleason scores and immunoexpressions of PSA, PAP, and P504S in prostatic tissues were analyzed. Results The Gleason score was higher in patients with metastatic prostate cancer thanin those with non-metastatic prostate cancer; and the rank-sum test showed there was a significant difference between the two groups （P〈0.05）. As compared with those aged ≤ 71, the positive immune expressions of PSA and PAP equal to or more than （＋＋）were significantly increased in patients aged ≥ 71 （P〈0.05）. 71 of the 81 patients were positive with P504S expression, accounting for 87.7 percent. Conclusions The Gleason score and immunoexpressions of PSA, PAP, and P504S can accurately assess the severity of prostate cancer and promote the quality of follow-up of nursing and consulting.

关 键 词：转移性 前列腺癌 GLEASON评分 免疫表达 

分 类 号：R737.25[医药卫生—肿瘤]